Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. 

We are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. Our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. We are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.

Janus Henderson Investors

Franklin Templeton

Access Biotechnology

Atlas Venture

Boxer Capital

Canaan Partners

T. Rowe Price

Viking Global Investors

Perceptive Advisors

RA Capital Management

Day One Biopharmaceuticals

Molly’s advice for others going through a pediatric low-grade glioma (#pLGG) journey is to keep a list of questions to ask the doctor — even the small things. To hear more stories from people living with pLGG and tips for navigating a challenging diagnosis, visit: https://lnkd.in/eDtwpMUz

#RethinkpLGG

Today, we celebrate and support raising awareness for #RareDiseaseDay! More than 300 million people around the world live with a rare disease. Though considered a rare #cancer, pediatric low-grade glioma (pLGG) accounts for approximately 30% of all childhood brain tumors. There is a considerable need for increased visibility and awareness for #pLGG and all rare diseases. 

Head of R&D and co-founder Samuel Blackman shares the Day One journey to reshape #pediatriccancer drug development in this article for the Pediatric Cancer Research Foundation’s Profectus blog, Turning “One Day” into “Day One”: https://bit.ly/3URbMzF

Our co-founder and Head of R&D, Samuel Blackman, recently sat down with Michael Pietrack of The Pharmaverse Podcast to discuss how Sam’s expedition to the base camp of Mount Everest influenced his #leadership philosophy. Sam speaks to the power of vulnerability and camaraderie and how these universal lessons can positively impact the compassionate care provided to young patients and their families. Watch the full episode here: https://lnkd.in/epZpSG3C 

Today, on #NationalCaregiversDay, we spotlight the selfless care, love and support #caregivers provide to those who need it most. Remember to thank a #caregiver, not only today, but every day, for helping our loved ones live better lives.

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	69K -	202K 192.75%	1.74M 763.37%	260K 85.09%	2.58M 890.77%
accumulated other comprehensive income loss				-71K -	9K 112.68%
cash and cash equivalents	27.33M -	43.73M 59.99%	284.31M 550.18%	85.26M 70.01%	230.78M 170.68%
cash and short term investments	27.33M -	43.73M 59.99%	284.31M 550.18%	342.27M 20.39%	366.35M 7.03%
common stock	2M -	2M 0%	6K 99.70%	7K 16.67%	9K 28.57%
deferred revenue		1.57M -	6.61M 320.97%		25.48M -
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt		204K -	16K 92.16%	408K 2,450%
long term investments
net debt	-27.33M -	-43.33M 58.52%	-284.09M 555.70%	-84.45M 70.27%	-230.38M 172.80%
net receivables
other assets
other current assets			1.01M -	1.01M 0.89%	2.35M 133.80%
other current liabilities	1.95M -	27K 98.62%	104K 285.19%	15.95M 15,236.54%	1.04M 93.47%
other liabilities
other non current assets		107K -	169K 57.94%	469K 177.51%	214K 54.37%
other non current liabilities		91.96M -
othertotal stockholders equity	-5.38M -	-5.07M 5.78%	-6K 99.88%	64K 1,166.67%	805.11M 1,257,879.69%
preferred stock	5.49M -	5.70M 3.92%
property plant equipment net		483K -	284K 41.20%	719K 153.17%	560K 22.11%
retained earnings	-12.78M -	-56.84M 344.63%	-127.49M 124.28%	-269.67M 111.53%	-458.58M 70.06%
short term debt		198K -	204K 3.03%	405K 98.53%	408K 0.74%
short term investments				257.01M -	135.56M 47.25%
tax assets
tax payables
total assets	27.34M -	45.66M 67.02%	289.82M 534.72%	349.06M 20.44%	376.05M 7.73%
total current assets	27.34M -	45.07M 64.86%	289.37M 542.03%	347.87M 20.22%	375.27M 7.88%
total current liabilities	2.02M -	2.00M 1.24%	8.66M 333.72%	16.61M 91.93%	29.51M 77.60%
total debt		402K -	220K 45.27%	813K 269.55%	408K 49.82%
total investments				257.01M -	135.56M 47.25%
total liabilities	32.52M -	94.16M 189.51%	8.67M 90.79%	17.02M 96.28%	29.51M 73.34%
total liabilities and stockholders equity	27.34M -	45.66M 67.02%	-118.81M 360.21%	-252.65M 112.64%	376.05M 248.84%
total non current assets		590K -	453K 23.22%	1.19M 162.25%	774K 34.85%
total non current liabilities	30.50M -	92.17M 202.15%	16K 99.98%	408K 2,450%
total stockholders equity	-10.67M -	-54.20M 407.87%	-127.49M 135.19%	-269.67M 111.53%	346.54M 228.51%

COM:DAYONEBIO

Day One Bio

Last Close

13.34

22/11 21:00

Market Cap

1.29B

Beta: -

Volume Today

591.56K

Avg: -

Preview